Total Payments
$3,781
2024 Payments
$622.95
Companies
35
Transactions
133
Medicare Patients
9,053
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$3,162 (83.6%)
Travel$619.06 (16.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,162 | 131 | 83.6% |
| Travel and Lodging | $619.06 | 2 | 16.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $931.55 | 8 | $0 (2023) |
| Collegium Pharmaceutical, Inc. | $558.57 | 33 | $0 (2024) |
| SCILEX PHARMACEUTICALS INC. | $373.21 | 20 | $0 (2024) |
| Medtronic, Inc. | $249.73 | 7 | $0 (2024) |
| PAINTEQ LLC | $167.96 | 1 | $0 (2021) |
| Vertos Medical, Inc. | $166.99 | 3 | $0 (2022) |
| Nevro Corp. | $156.90 | 6 | $0 (2023) |
| Abbott Laboratories | $155.28 | 6 | $0 (2023) |
| ABBVIE INC. | $149.89 | 9 | $0 (2024) |
| VGI Medical, LLC | $101.68 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $622.95 | 35 | Collegium Pharmaceutical, Inc. ($304.12) |
| 2023 | $855.47 | 35 | Scilex Pharmaceuticals Inc. ($203.68) |
| 2022 | $827.00 | 30 | Boston Scientific Corporation ($223.74) |
| 2021 | $486.71 | 19 | PAINTEQ LLC ($167.96) |
| 2020 | $89.93 | 5 | Abbott Laboratories ($27.05) |
| 2019 | $85.08 | 4 | Abbott Laboratories ($59.46) |
| 2018 | $813.76 | 5 | BOSTON SCIENTIFIC CORPORATION ($672.45) |
All Payment Transactions
133 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Analgesic | ||||||
| 12/04/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $22.26 | General |
| Category: Opioid Analgesic | ||||||
| 11/13/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $21.56 | General |
| Category: Opioid Analgesic | ||||||
| 11/12/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 10/22/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $19.89 | General |
| Category: Opioid Analgesic | ||||||
| 10/02/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $20.66 | General |
| Category: Opioid Analgesic | ||||||
| 09/26/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: Analgesic | ||||||
| 09/24/2024 | Electronic Waveform Lab, Inc. | — | Food and Beverage | Cash or cash equivalent | $13.86 | General |
| 09/18/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 09/10/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $17.44 | General |
| Category: Opioid Analgesic | ||||||
| 08/29/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $22.39 | General |
| Category: Opioid Analgesic | ||||||
| 08/22/2024 | ABBVIE INC. | QULIPTA (Drug), BOTOX | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: NEUROSCIENCE | ||||||
| 08/07/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $15.46 | General |
| Category: Opioid Analgesic | ||||||
| 07/16/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $8.32 | General |
| Category: Opioid Analgesic | ||||||
| 07/12/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $19.75 | General |
| Category: Opioid Analgesic | ||||||
| 06/25/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $5.85 | General |
| Category: Opioid Analgesic | ||||||
| 06/12/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Gastroenterology | ||||||
| 06/10/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 06/06/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: NEUROSCIENCE | ||||||
| 06/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Gastroenterology | ||||||
| 05/30/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $18.76 | General |
| Category: Opioid Analgesic | ||||||
| 05/06/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $15.95 | General |
| Category: Opioid Analgesic | ||||||
| 04/24/2024 | Azurity Pharmaceuticals, Inc. | HORIZANT (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: CEREBROVASCULARCNS | ||||||
| 04/23/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 207 | 405 | $496,538 | $52,225 |
| 2022 | 35 | 3,347 | 19,832 | $1.4M | $439,429 |
| 2021 | 33 | 2,914 | 28,408 | $1.2M | $437,538 |
| 2020 | 37 | 2,585 | 23,738 | $954,087 | $367,674 |
Total Patients
9,053
Total Services
72,383
Medicare Billing
$1.3M
Procedure Codes
113
All Medicare Procedures & Services
113 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 77 | 202 | $185,743 | $21,010 | 11.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 26 | 96 | $192,729 | $18,276 | 9.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 59 | $83,408 | $8,661 | 10.4% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2023 | 24 | 24 | $20,229 | $2,497 | 12.3% |
| 95921 | Testing of autonomic nervous system function and heart rate response to deep breathing | Office | 2023 | 24 | 24 | $14,430 | $1,781 | 12.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 695 | 1,255 | $337,468 | $129,167 | 38.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 332 | 597 | $107,460 | $42,421 | 39.5% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 195 | 243 | $197,700 | $37,419 | 18.9% |
| 97110 | Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes | Office | 2022 | 128 | 1,206 | $84,732 | $24,270 | 28.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 281 | 384 | $127,360 | $23,466 | 18.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 106 | 126 | $43,460 | $18,184 | 41.8% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Office | 2022 | 86 | 96 | $30,996 | $16,526 | 53.3% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2022 | 60 | 65 | $31,334 | $16,070 | 51.3% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2022 | 43 | 54 | $27,324 | $11,765 | 43.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 83 | 83 | $26,784 | $10,327 | 38.6% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2022 | 36 | 47 | $16,048 | $9,750 | 60.8% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2022 | 17 | 18 | $15,282 | $9,063 | 59.3% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 36 | 36 | $27,400 | $8,798 | 32.1% |
| 76942 | Ultrasonic guidance for needle placement | Office | 2022 | 116 | 146 | $18,011 | $7,111 | 39.5% |
| 72148 | Mri scan of lower spinal canal without contrast | Office | 2022 | 40 | 40 | $19,263 | $6,772 | 35.2% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2022 | 54 | 60 | $11,912 | $5,336 | 44.8% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2022 | 35 | 45 | $8,100 | $4,991 | 61.6% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2022 | 17 | 18 | $7,784 | $4,949 | 63.6% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 24 | 24 | $20,500 | $4,720 | 23.0% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Office | 2022 | 42 | 45 | $9,760 | $4,677 | 47.9% |
About Dr. Michael Silva, M.D
Dr. Michael Silva, M.D is a Pain Medicine healthcare provider based in North Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2014. The National Provider Identifier (NPI) number assigned to this provider is 1366856361.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Silva, M.D has received a total of $3,781 in payments from pharmaceutical and medical device companies, with $622.95 received in 2024. These payments were reported across 133 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($3,162).
As a Medicare-enrolled provider, Silva has provided services to 9,053 Medicare beneficiaries, totaling 72,383 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 113 distinct procedure/service records.
Ad
Practice Information
- Specialty Pain Medicine
- Location North Miami, FL
- Active Since 06/17/2014
- Last Updated 10/22/2025
- Taxonomy Code 207LP2900X
- Entity Type Individual
- NPI Number 1366856361
Products in Payments
- SPECTRA WAVEWRITER (Device) $672.45
- XTAMPZA (Drug) $558.57
- ZTLido (Drug) $360.28
- Superion Indirect Decompression System (Device) $191.84
- INTELLIS ADAPTIVESTIM (Device) $171.77
- PAINTEQ (Device) $167.96
- mild Device Kit (Device) $166.99
- UBRELVY (Drug) $121.53
- SiJoin (Device) $101.68
- Proclaim Family of SCS IPGs (Device) $86.51
- Omnia (Device) $80.76
- Qutenza (Drug) $78.22
- N/A (Device) $77.21
- HORIZANT (Drug) $69.27
- WaveWriter Alpha Prime 16 (Device) $67.26
- NALOCET (Drug) $56.41
- RELISTOR (Drug) $56.05
- PROCLAIM (Device) $55.61
- KYPHON EXPRESS II KYPHOPAK TRAY (Device) $49.75
- GRALISE (Drug) $46.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.